Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tomaralimab
- Development stage
- Phase 2
- Lead developer
- Neuramedy
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Tomaralimab is a humanized IgG4 monoclonal antibody that targets toll-like receptor 2 (TLR2). It acts as an antagonist, blocking TLR2-mediated signaling and thereby inhibiting inflammation. Tomaralimab is designed to prevent ischemia/reperfusion tissue injury and has been investigated for conditions such as delayed graft function after kidney transplantation, myelodysplastic syndromes, and Alzheimer's disease. The drug was initially developed by Opsona Therapeutics and is currently being developed by Neuramedy. Its mechanism involves binding to a specific epitope on the extracellular domain of TLR2, preventing its heterodimerization with TLR1 or TLR6 and silencing downstream inflammatory signaling[1][5][7].
- Brand names
- tomaralimab
- Other names
- TomaralimabHumanized IGG4 monoclonal antibody against toll-like receptor 2 for prevention of ischemia/reperfusion tissue injuryAnti-TLR2 monoclonal antibodyAnti-TLR-2 monoclonal antibodyAnti-TLR 2 monoclonal antibodyAnti-Toll-like receptor 2 monoclonal antibody
02
Targets
TLR2 (Toll-like Receptor 2)
Beyond the preview
Go deeper on tomaralimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tomaralimab.